Roche partner Chugai launches Zelboraf in Japan; NICE approves Sovaldi, Olysio; FDA postpones Remicade biosim meeting;

@FiercePharma: Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Sidelined after tampering incident, GSK's alli is back on sale. Report | Follow @CarlyHFierce

> Roche ($RHHBY) partner Chugai said it launched the targeted melanoma fighter Zelboraf in Japan. Release

> The National Institute for Health and Care Excellence gave final approval to two drugs to treat hepatitis C, Gilead Sciences' ($GILD) Sovaldi (sofosbuvir) and Johnson & Johnson's ($JNJ) Olysio (simeprevir), but many National Health Service patients will have to wait till July 31 for Sovaldi. Release

> The FDA postponed an advisory panel review of Celltrion and Hospira's ($HSP) Remsima, a biosimilar version of the anti-inflammatory drug Remicade, which is marketed in the U.S. by Johnson & Johnson and Merck ($MRK). Report

> Actavis' ($ACT) superbug antibiotic Avycaz won FDA approval to treat resistant infections of the urinary tract on its own, and abdominal infections in combination with metronidazole. Report

> The Slovenian drugmaker Krka saw 2014 sales drop to 1.19 billion euros ($1.35 billion) from 1.2 billion in 2013, with profits down to 166.2 million euros. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: In a medical first, three patients receive prosthetic hands in place of disabled ones. Article | Follow @FierceMedDev

@VarunSaxena2: Roche, BioMed X to jointly run diagnostics incubator in Germany. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Cyberonics and Sorin to form U.K.-based company valued at $2.7B, aiming to boost hospital offerings. More from Bloomberg | Follow @EmilyWFierce

> Indian diagnostics company Thyrocare aims for $100M IPO. News

> FDA warns manufacturer of failing to report corrections to its device disinfection system. Report

Biotech News

@FierceBiotech: After painful odyssey, Newron wins European OK for Parkinson's add-on. News | Follow @FierceBiotech

@JohnCFierce: Top story of the week: Exclusive: Pfizer is once again cutting back R&D staff in reorganization. Report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online and subscribe on iTunes. | Follow @DamianFierce

> Amgen completes PhIII trifecta as AMG416 goes head-to-head with Sensipar. Article

> Growing Dicerna moves into Cambridge supercluster. News

> Hospira and Celltrion hit a speed bump in their biosimilar dash. More

> Actavis wins FDA approval for a new 'superbug' antibiotic. Report

Vaccines News

> NewLink nets $20M Ebola milestone from Merck. Item

> Valeant touts PhII Provenge data following Dendreon buy. More

> Takeda places vaccines unit in Singapore to push for global growth. Article

> Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results. Story

> Pfizer trumpets positive Trumenba data ahead of ACIP vote. Report

Pharma Manufacturing News

> Impax reports significant jump in revenues as it gets plant problems behind it. Report

> Unused Forest Labs facility snapped up by Aprecia Pharmaceuticals. News

> New Jersey compounder indicted over unsanitary manufacturing. Story

> Bharat, Serum Institute ramp up production of their swine flu vaccines. Item

> Federal judge cuts off Maine's Internet drug supply chain. Article

And Finally... After South Korea's top court struck down a legal ban on adultery, shares of makers of contraceptives soared. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.